As of Jul 31, 2026, Pharmacyte Biotech, Inc. had total assets of $36.7 million and total liabilities of $6.9 million. Total assets were down 18.6% from a year earlier. Stockholders' equity was $27.5 million. Cash and investments were $17.8 million. The current ratio, current assets divided by current liabilities, was 40.30.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 30, 2026
|
FY 2025
Apr 30, 2025
|
FY 2024
Apr 30, 2024
|
FY 2023
Apr 30, 2023
|
FY 2022
Apr 30, 2022
|
FY 2021
Apr 30, 2021
|
FY 2020
Apr 30, 2020
|
FY 2019
Apr 30, 2019
|
FY 2018
Apr 30, 2018
|
FY 2017
Apr 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash |
18
+34.6%
|
19
+22.6%
|
15
-69.8%
|
50
-26.2%
|
68
|
—
|
—
|
—
|
—
|
—
|
—
|
| Short-term investments |
0
-62.0%
|
0
-30.7%
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Cash and investments |
18
+32.7%
|
19
+21.4%
|
16
-69.0%
|
50
-26.2%
|
68
|
—
|
—
|
—
|
—
|
—
|
—
|
| Total current assets |
31
+62.1%
|
37
+67.2%
|
22
-55.6%
|
50
-26.0%
|
68
-20.3%
|
85
+3657.6%
|
2
+119.3%
|
1
+58.8%
|
1
-49.1%
|
1
-63.7%
|
4
+74.2%
|
| Total assets |
37
-18.6%
|
47
-15.3%
|
55
-7.9%
|
60
-18.3%
|
73
-19.1%
|
91
+1124.0%
|
7
+20.1%
|
6
+6.6%
|
6
-9.8%
|
6
-26.0%
|
9
+21.0%
|
| Liabilities and equity | |||||||||||
| Accounts payable |
0
-16.1%
|
0
-32.1%
|
0
+2.5%
|
0
+203.5%
|
0
-37.5%
|
0
+19.2%
|
0
-7.3%
|
0
+52.5%
|
0
-65.4%
|
0
-3.6%
|
0
+8.8%
|
| Total current liabilities |
1
-27.5%
|
1
-71.6%
|
3
-60.7%
|
7
+1165.2%
|
1
-16.7%
|
1
-2.8%
|
1
-29.7%
|
1
+38.8%
|
1
+15.3%
|
1
+11.0%
|
1
-9.0%
|
| Total liabilities |
7
+354.1%
|
12
+259.2%
|
3
-83.9%
|
20
+3376.0%
|
1
-16.7%
|
1
-2.8%
|
1
-32.7%
|
1
+45.1%
|
1
+15.3%
|
1
+11.0%
|
1
-9.0%
|
| Stockholders' equity |
28
-36.9%
|
33
-35.8%
|
52
+87.7%
|
28
-62.0%
|
73
-19.2%
|
90
+1246.2%
|
7
+31.3%
|
5
+1.0%
|
5
-12.6%
|
6
-28.7%
|
8
+24.0%
|
| Ratios | |||||||||||
| Current ratio |
40.30x
|
45.28x
|
7.68x
|
6.80x
|
116.18x
|
121.38x
|
3.14x
|
1.01x
|
0.88x
|
1.99x
|
6.10x
|
| Return on equity |
-58.69%
|
-58.34%
|
59.08%
|
1.21%
|
-5.94%
|
-4.71%
|
-53.17%
|
-75.20%
|
-80.71%
|
-118.38%
|
-54.95%
|
| Return on assets |
-43.98%
|
-41.55%
|
55.57%
|
0.56%
|
-5.89%
|
-4.68%
|
-47.96%
|
-62.06%
|
-70.34%
|
-106.49%
|
-51.27%
|
| Book value per share |
2.56
|
3.10
|
7.64
|
3.44
|
4.33
|
4.34
|
4.20
|
4.66
|
0.00
|
0.01
|
0.01
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.